Imperial College London
Alternate

Professor Francis Drobniewski

Faculty of Medicine, Department of Infectious Disease

Chair in Global Health and Tuberculosis
 
 
 
//

Contact

 

f.drobniewski

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gonzalo:2022:10.3390/antibiotics11081070,
author = {Gonzalo, X and Drobniewski, F},
doi = {10.3390/antibiotics11081070},
journal = {Antibiotics},
pages = {1--10},
title = {Are the newer carbapenems of any value against tuberculosis},
url = {http://dx.doi.org/10.3390/antibiotics11081070},
volume = {11},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Our aim was to assess whether newer carbapenems with a better administration profile than meropenem (ertapenem, faropenem and tebipenem) were more effective against Mycobacterium tuberculosis including M/XDRTB and determine if there was a synergistic/antagonistic effect with amoxicillin or clavulanate (inhibitor of beta-lactamases that MTB possesses) in vitro. Whilst meropenem is given three times a day intravenously, ertapenem, though given parenterally, is given once a day, faropenem and tebipenem are given orally. Eighty-two clinical drug-sensitive and -resistant MTB strains and a laboratory strain, H37Rv, were assessed by a microdilution methodology against ertapenem, faropenem, tebipenem and meropenem with and without amoxicillin or clavulanic acid. Ertapenem showed a limited activity. The addition of amoxicillin and clavulanate did not translate into significant improvements in susceptibility. Sixty-two isolates (75.6%) exhibited susceptibility to faropenem; the addition of amoxicillin and clavulanate further reduced the MIC in some isolates. Faropenem showed a limited activity (MIC of 8 mg/L or lower) in 21 strains completely resistant to meropenem (MIC of 16 mg/L or higher). Fifteen of the meropenem-resistant strains were susceptible to tebipenem. Carbapenems’ activity has been reported extensively. However, there remains uncertainty as to which of them is most active against TB and what the testing methodology should be.
AU  - Gonzalo,X
AU  - Drobniewski,F
DO  - 10.3390/antibiotics11081070
EP  - 10
PY  - 2022///
SN  - 2079-6382
SP  - 1
TI  - Are the newer carbapenems of any value against tuberculosis
T2  - Antibiotics
UR  - http://dx.doi.org/10.3390/antibiotics11081070
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000846390600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2079-6382/11/8/1070
UR  - http://hdl.handle.net/10044/1/99822
VL  - 11
ER  -
Download